Hepatitis Drugs Market Size is Estimated to grow at a CAGR of 25.0% during the forecast period
The global hepatitis drugs market is
estimated to grow at a CAGR of 25.0% during the forecast period
2022-2030. Hepatitis is recognized as one of the leading causes of death
worldwide. The consequences resulting from hepatitis type B account for around
0.8 million deaths annually, while hepatitis C is accountable for about 0.5
million deaths annually.
An inflammatory disease that seriously damages the liver is
called hepatitis. The illness can also have a major impact on a person's brain
and digestive system. It may result in a chronic, semi-acute, or acute
infection. Any of the five hepatotropic viruses—A, B, C, D, and E—can cause
viral hepatitis, which is the most frequent kind of hepatitis. HAV, HBV, and
HCV are the three main forms of hepatitis that are currently recognized. In
addition to viral and bacterial infections, autoimmune disorders, excessive
alcohol use, toxins, and some prescription drugs can also contribute to the
illness.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/hepatitis-drugs-market
GROWTH DRIVERS
The main factors propelling the growth of the global
hepatitis drugs market are the increasing prevalence of various forms of
hepatitis cases worldwide, the growing need for medications to treat and manage
hepatitis cases, rising public awareness, the aging population, the rising cost
of healthcare, investments made by public and private organizations in the
development of hepatitis drugs and therapies, the increasing number of new
product launches, and regulatory approvals of hepatitis drugs by authorities.
Furthermore, industry participants have been placing a
greater emphasis on research and development initiatives in order to secure
approval for a range of clinical trials before their future HCV and HBV
medications are made publicly available. In addition, the launch of novel
treatments like interferon-free combination regimens and second-generation
DAAs, which are anticipated to achieve greater SVR and cause fewer side effects
than existing treatments, is anticipated to create enormous growth prospects
for the global hepatitis drugs market in
the years to come.
HEPATITIS DRUGS MARKET SEGMENTATION
By Drug Class
· Interferon
Alphas
· HIV
NRTIs
· Nucleotide
Polymerase / NS5A Inhibitor Combinations
· Hepatitis
C Protease / NS5A Inhibitor Combinations
· NS5A
Inhibitors
· Nucleotide
Polymerase Inhibitors
· Nucleoside
Analogue Antivirals
· Thrombopoiesis
Stimulating Agents
By Disease Type
· Hepatitis
A
· Hepatitis
B
· Hepatitis
C
· Others
By Route of Administration
· Oral
· Injection
By Distribution Channel
· Hospital
Pharmacies
· Retail
Pharmacies
· Online
Pharmacies
By Region
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
KEY COMPANIES IN HEPATITIS DRUGS MARKET
· Novartis
AG
· Dynavax
Technologies Corporation
· F.
Hoffmann-La Roche Ltd.
· Mitsubishi
Tanabe Pharma Corporation
· Bristol-Myers
Squibb Company
· LAURUS
Labs
· Gilead
Sciences Inc.
· Abbvie
Inc.
· Johnson
& Johnson
· Merck
& Co. Inc.
· GlaxoSmithKline
plc
· Vertex
Pharmaceuticals Inc.
· Zydus
Cadila
· Hetero
Healthcare Limited
· Cipla
Inc.
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/hepatitis-drugs-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment